Hypohidrosis

Abnormally diminished or absent perspiration. Both generalized and segmented (reduced or absent sweating in circumscribed locations) forms of the disease are usually associated with other underlying conditions.

Also Known As:

Networked: 193 relevant articles (6 outcomes, 9 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Hyperhidrosis
2.	Pain (Aches)
3.	Fever (Fevers)
4.	Hereditary Sensory and Autonomic Neuropathies (HSAN)
5.	Mental Retardation (Idiocy)

Experts

1.	Indo, Y: 7 articles (10/2012 - 01/2000)
2.	Mardy, S: 4 articles (02/2001 - 01/2000)
3.	Katayama, Ichiro: 3 articles (01/2015 - 04/2009)
4.	Matsuda, I: 3 articles (02/2001 - 01/2000)
5.	Miura, Y: 3 articles (02/2001 - 01/2000)
6.	Endo, F: 3 articles (02/2001 - 01/2000)
7.	Zlotnik, Alexander: 2 articles (11/2015 - 10/2010)
8.	Bodner, Lipa: 2 articles (11/2015 - 03/2013)
9.	Gruenbaum, Shaun E: 2 articles (11/2015 - 10/2010)
10.	Murota, Hiroyuki: 2 articles (01/2015 - 02/2014)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Hypohidrosis:

1.	Acetylcholine (Acetylcholine Chloride)FDA Link 01/01/2008 - "The symptom of dry mouth often accompanies the less apparent symptom of hypohidrosis because the muscarinic M(3) acetylcholine receptor type predominates at both sweat and salivary glands. " 01/01/2008 - "As acetylcholine is the principal neuroeccrine mediator, anhidrosis is one of the clinical hallmarks by which acute anticholinergic toxicity may be recognized. " 03/01/1982 - "The alteration of the sudomotor response to intradermal acetylcholine during the course of the illness suggests that the diagnostic utility of pharmacologic sweat tests may be time dependent, limited to a relatively early period following onset of anhidrosis." 03/01/1982 - "Intradermal acetylcholine produced localized sweating in areas of thermoregulatory anhidrosis five months after the onset of symptoms but failed to do so at two years. " 01/01/2014 - "Decreased expression of acetylcholine esterase in cholinergic urticaria with hypohidrosis or anhidrosis."
2.	onabotulinumtoxinA (Botox)FDA Link 02/01/2014 - "The area of anhidrosis SC was significantly greater with CBTX-A than onabotulinumtoxinA. " 03/01/2012 - "The results showed that incobotulinumtoxinA and onabotulinumtoxinA displayed comparable spread at 6 weeks (maximal area of anhidrosis within 6 weeks) and area under the effect curve (AUEC) over 6 months. " 02/01/2014 - "When BoNTAs were different, the anhidrosis ID area was significantly greater with CBTX-A than onabotulinumtoxinA, the vertical dimension was significantly longer with CBTX-A ID than onabotulinumtoxinA ID and the horizontal dimension was significantly greater with CBTX-A ID than onabotulinumtoxinA ID. " 01/01/2007 - "Patients received 3 U/injection of BoNTA(1) (BOTOX, Allergan, Inc.) and were randomly assigned to receive BoNTA(2) (Dysport, Ipsen Ltd.) at a dose ratio of 1:2.5, 1:3, or 1:4. The area of anhidrosis was highlighted using iodine and starch and determined by software from standardized photography. "
3.	Prednisolone (Predate)FDA LinkGeneric 04/01/2006 - "We report a 34-year-old man with acquired idiopathic hypohidrosis successfully treated with prednisolone. " 01/01/2000 - "Oral prednisolone improved acetylcholine-induced sweating in Sjögren's syndrome-related anhidrosis."
4.	abobotulinumtoxinAFDA Link 03/01/2012 - "However, abobotulinumtoxinA, when assuming a 1:2.5 injection volume ratio, produced a statistically significantly greater maximal area of anhidrosis within 6 weeks and AUEC over 6 months compared with incobotulinumtoxinA. " 01/01/2007 - "Patients received 3 U/injection of BoNTA(1) (BOTOX, Allergan, Inc.) and were randomly assigned to receive BoNTA(2) (Dysport, Ipsen Ltd.) at a dose ratio of 1:2.5, 1:3, or 1:4. The area of anhidrosis was highlighted using iodine and starch and determined by software from standardized photography. "
5.	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/01/2013 - "Administration of cyclosporine markedly improved the patient's condition and sympathetic skin response; thus cyclosporine may be effective for treating anhidrosis in patients with autoimmune disorders." 01/01/2013 - "We report a case of acquired generalized anhidrosis successfully treated with cyclosporine. " 01/01/2013 - "Acquired generalized anhidrosis: review of the literature and report of a case with lymphocytic hidradenitis and sialadenitis successfully treated with cyclosporine."
6.	CreatinineIBA 11/01/2003 - "After 12 months of therapy the mean creatinine clearance increased, there was significant improvement in the acroparaesthesias and in the hypohidrosis. "
7.	topiramate (Topamax)FDA LinkGeneric 02/01/2010 - "The aim of this study was to determine the incidence and define the clinical characteristics of hypohidrosis-related symptoms with topiramate in pediatric patients. " 11/01/2008 - "In our 2 cases with hypohidrosis related to topiramate, electrophysiological study showed normal function of both beta and delta sensory fibers and absent sympathetic skin responses that recovered to normal after topiramate discontinuation. " 11/01/2008 - "A neurophysiological study has been performed on 2 children who have developed hypohidrosis under topiramate treatment. " 11/01/2008 - "The aim of our study is to detect a possible skin innervation involvement as the mechanism underlying hypohidrosis in children treated with topiramate. " 11/01/2008 - "Electrophysiological study in 2 children with transient hypohidrosis induced by topiramate."
8.	Type A Botulinum Toxins (Botulinum A Toxin)FDA Link 01/01/2003 - "We treated the patient with 2 separate series of subcutaneous botulinum toxin type A injections to the right upper abdomen and achieved anhidrosis in 5 weeks. " 04/01/2002 - "Intracutaneous injections of botulinum toxin type A (BTXA) have recently been shown to induce an effective but temporary anhidrosis, usually for 4 to 6 months. " 05/01/2008 - "The purpose of this study was to investigate the efficacy and persistence of the hypohidrosis induced by iontophoresis of botulinum toxin type A in patients with palmar hyperhidrosis. "
9.	Terbutaline (Brethaire)FDA LinkGeneric 07/01/2008 - "This quantitative intradermal terbutaline sweat test should be a useful aid to the study of equine sweating and anhidrosis."
10.	Amyloid (Amyloid Fibrils)IBA 09/01/1998 - "Anhidrosis of the distal lower limbs is a prominent feature of FAP type I. Qualitative and morphometric study of amyloid deposition, eccrine glands, and their innervation in nine patients with FAP type I (duration of sensory symptoms, 8.4 +/- 3.9 years [mean +/- SD]; range, 3 to 15 years) and seven control subjects. "

Therapies and Procedures

1.	Sympathectomy (Sympathectomies) 04/01/2011 - "In this series, we did not find any significant difference between T2-T4 sympathectomy and T3-T4 sympathicotomy in terms of postsurgical palmar anhidrosis or onset of compensatory hyperhidrosis, while both methods show high efficacy for remission of palmar hyperhidrosis. " 09/01/2007 - "He had previously received bilateral thoracic sympathectomy for axillary hyperhidrosis at another hospital, and was known to have upper body and limb anhidrosis. "
2.	Vertical Dimension (Occlusion Vertical Dimension) 02/01/2014 - "When BoNTAs were different, the anhidrosis ID area was significantly greater with CBTX-A than onabotulinumtoxinA, the vertical dimension was significantly longer with CBTX-A ID than onabotulinumtoxinA ID and the horizontal dimension was significantly greater with CBTX-A ID than onabotulinumtoxinA ID. "
3.	Anesthesia 02/01/2002 - "Anesthesia for patients with congenital insensitivity to pain and anhidrosis: a questionnaire study in Japan." 05/01/2014 - "They may be accompanied by hypo or anesthesia, alopecia, and hypo or anhidrosis. " 09/01/2009 - "[Anesthesia in a patient with congenital insensitivity to pain and anhidrosis]." 02/01/2002 - "We clarified the following three important points: anesthesia is necessary, temperature management must be maintained, and there must be sufficient perioperative sedation in the anesthetic management of patients with congenital insensitivity to pain and anhidrosis."
4.	Electrodes (Electrode) 02/01/1977 - "In our study 90% of the patients treated developed anhidrosis on both the anode and cathode treated palms or soles. "
5.	Injections 01/01/2003 - "We treated the patient with 2 separate series of subcutaneous botulinum toxin type A injections to the right upper abdomen and achieved anhidrosis in 5 weeks. " 04/01/2002 - "Intracutaneous injections of botulinum toxin type A (BTXA) have recently been shown to induce an effective but temporary anhidrosis, usually for 4 to 6 months. " 04/01/2000 - "Recently, low-dose intracutaneous injections of botulinum toxin A have been shown to induce a temporary anhidrosis, with relapses occurring usually after 4 to 6 months. " 12/01/2003 - "Sweat tests were carried out before botulinum toxin type B injections, and at 3 wk, 3 mo, and 6 mo. We studied focal anhidrosis by iodine-starch staining and by capacitance hygrometry after carbachol iontophoresis, according to the quantitative sudomotor axon reflex test (QSART). "